Navigation Links
Nventa updates progress of cervical dysplasia trial with new HspE7
Date:10/18/2007

release are cautioned that such statements or information are only predictions, and that the Company's actual future results or performance may be materially different.

Forward-looking statements or information in this press release include, but are not limited to, statements or information concerning: the number of cohorts and patients and the expected dosing amounts in the Phase 1 trial; successful completion of the Phase 1 trial; the launching of a Phase 2 clinical trial in patients with high-grade cervical intraepithelial neoplasia (CIN2/3); the possibility of a second Phase 2 trial in HIV-positive low-grade CIN patients.

Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments to be materially different from results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, the possibility that we will not be able to recruit patients for our trials in a timely manner; our need for capital, risks associated with requirements for approvals by government agencies such as the FDA before products can be tested in clinical trials; the possibility that such government agency approvals will not be obtained in a timely manner or at all or will be conditioned in a manner that would impair our ability to advance development; risks associated with the requirement that a drug be found safe and effective after extensive clinical trials: our dependence on suppliers, collaborative partners and other third parties and the prospects and timing for negotiating supply agreements, corporate collaborations or licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Merge announces sofware updates, upcoming acquisition
2. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
3. Solinus updates MailFoundry anti-spam hardware, switching to Linux
4. Wingra Technologies updates data migration software
5. Wisconsin cities make progress on wireless Internet coverage
6. Doyle laments lack of progress on stem cell bill
7. U.S. health system could undermine EHR progress
8. Stem-cell controversies slow progress
9. VC trends, company progress discussed at Mason Wells portfolio meeting
10. Can you keep ahead of progress? An exclusive interview with Rick Smith of iNoc
11. Furious pace of Midwest biotech events marks progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Arizona (PRWEB) January 15, 2014 2013 ... for Scottsdale’s Brain State Technologies®. They saw continued independent ... Medical Center who were awarded a $1 million grant ... published in “Brain and Behavior” a peer reviewed journal, ...
(Date:1/15/2014)... AudioNotch is the internet's leading provider of ... of tinnitus. Patients listen to sound therapy that is ... of weeks to months, their tinnitus volume decreases. , AudioNotch ... Music and Notched White Noise. Now, AudioNotch is pleased to ...
(Date:1/14/2014)... 14, 2014 Date: Friday, April 11, 2014 ... Country Club, 1360 Almshouse Road, Warrington, Pa. , ... solely dedicated to finding a cure for hepatitis B and ... host its annual Crystal Ball on Friday, April 11 at ...
(Date:1/14/2014)... Diego, CA (PRWEB) January 14, 2014 ... on the products of cells grown under simulated embryonic ... international license agreement with Suneva Medical, Inc. for physician-dispensed ... (CCM). , This agreement is an amendment ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... in technology have provided people with many items ... phones with digital audio capabilities. Technology is evolving ... considered fantasy 10 years ago are now taken ... must consider and understand how technology may evolve ...
... co-authored this commentary with Michael J. Cronin, Ph.D., J.D., an ... , ,A look at the facts in the dispute over ... - and the history behind similar disputes - shows a ... will retain all of its patent rights, even if some ...
... is writing a series of articles on raising capital from investors. ... Most of the time when raising equity capital, the offering terms ... sheet . When dealing with angel investors , it ... , ,Sometimes prospective angel investors will want to negotiate the initial ...
Cached Biology Technology:Making deals with evolving technologies in mind 2Making deals with evolving technologies in mind 3Making deals with evolving technologies in mind 4Making deals with evolving technologies in mind 5WARF is likely to hold on to stem cell patent rights 2WARF is likely to hold on to stem cell patent rights 3WARF is likely to hold on to stem cell patent rights 4WARF is likely to hold on to stem cell patent rights 5WARF is likely to hold on to stem cell patent rights 6WARF is likely to hold on to stem cell patent rights 7WARF is likely to hold on to stem cell patent rights 8Capital-raising term sheets for angels and venture capitalists 2Capital-raising term sheets for angels and venture capitalists 3Capital-raising term sheets for angels and venture capitalists 4Capital-raising term sheets for angels and venture capitalists 5
(Date:4/17/2014)... development of stem cell therapies to cure a variety ... cell populations based on cell surface markers. Researchers from ... that is highly expressed in a type of stem ... describe in an article in BioResearch Open Access ... publishers. The article is available free on the ...
(Date:4/17/2014)... Occurring in about one per eight hundred births, Down ... frequent genetic cause of intellectual disability. It results from ... a third copy of chromosome 21 (1% of the ... his team in the Department of Genetic Medicine and ... Medicine, published in Nature , shed light on ...
(Date:4/17/2014)... Singh Thursday as a "Champion of Change" for ... in the residential, commercial and industrial sectors. , ... and Computer Engineering and director of Clemson,s Center ... leading the charge across the country to create ... driving policy changes at the local level to ...
Breaking Biology News(10 mins):Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... millions of people warding off winter,s chill with blazing ... about the potential health effects of the smoke released ... Chemical Society,s (ACS,) journal, Chemical Research in Toxicology ... lungs from wood smoke may have several adverse health ...
... , An ambitious hunt by Johns Hopkins scientists for actively ... the genome, anything but static, contains numerous pesky mobile elements ... variety of physical traits and disease risks. ... as outlined in the reference human genome to raw whole-genome ...
... , This release is available in Spanish . ... acids (AGPO-3) and the onset of depressive disorders is not new ... now is the brain mechanism by which diet can condition mental ... (France) and at the Faculty of Medicine and Odontology of the ...
Cached Biology News:Johns Hopkins researchers capture jumping genes 2Scientific research reveals brain alterations linking omega 3 deficit with depression 2Scientific research reveals brain alterations linking omega 3 deficit with depression 3
p230 trans Golgi Purified Anti-Human clone 15, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Goat polyclonal to Duffy / FY / DARC...
Guanylate Kinase Purified Anti-Mouse, Anti-Rat clone 28, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
... a 27kDa periplasmic enzyme from E. coli ... cyclic nucleotide monophosphate (NMP) intermediates. Slower hydrolysis ... to 3-NMPs (1). RNase ONE Ribonuclease is ... can cleave a phosophodiester bond between any ...
Biology Products: